Benchmark Co. analyst Bruce Jackson maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report) yesterday and set a price target of $3.00.
Bruce Jackson has given his Buy rating due to a combination of factors surrounding Unicycive Therapeutics. The company is on the brink of receiving FDA approval for its first product, Oxylanthanum Carbonate (OLC), which is designed to treat hyperphosphatemia in patients with chronic kidney disease on dialysis. This product offers a significant advantage over current treatments by reducing the pill burden from up to 12 chewable tablets a day to just three swallowable pills, potentially improving patient compliance and outcomes.
Additionally, the anticipated FDA approval and commercial launch of OLC in the second half of 2025 align with favorable market conditions. The expansion of Medicare patient access to phosphate binders and the inclusion of these products in the ESRD Prospective Payment System through the CMS TDAPA program will provide a financial tailwind. This program ensures favorable reimbursement for OLC for five years, which is expected to enhance its market potential and support its pricing strategy, similar to existing leading drugs in the category.
Jackson covers the Healthcare sector, focusing on stocks such as NeoGenomics, Humacyte, and Belite Bio, Inc. ADR. According to TipRanks, Jackson has an average return of -23.3% and a 26.01% success rate on recommended stocks.